Clinical Outcomes of Tamoxifen and Clomiphene Citrate in Intrauterine Insemination Cycles

Asifa Majeed, Divyashree PS, Rao KA

ABSTRACT

Background: Both selective estrogen receptor modulators, tamoxifen and clomiphene have been used for ovulation induction for patients with anovulatory infertility. The aim of this study is to compare the effectiveness of tamoxifen to clomiphene on clinical outcome in intrauterine insemination (IUI) cycles.

Materials and methods: It is a retrospective clinical study. Two hundred and seven women undergoing IUI cycles from July 2013 to July 2014 at Milann—The fertility centre, Bengaluru, India were analyzed. Tamoxifen was administered in the dose of 40 mg starting from day 2/3 of the menstrual cycle for a period of 5 days and clomiphene citrate (cc) was administered in the dose of 100 mg from day 2/3 of menstrual cycle for 5 days. Monitoring of ovulation was done by transvaginal ultrasound from day 5/6 till dominant follicle size was more than 18 mm. Highly purified human chorionic gonadotrophin (hCG) in the dose of 5000 IU was given. Double insemination was done at 24 and 36 hours. Luteal phase support was given in form of dydrogesterone 10 mg twice a day for 14 days. Serum beta-hCG was done after 14 days.

Result: In our study, 76 patients recieved clomiphene citrate (37%) and 126 patients received tamoxifen (62.9%). Both the groups were comparable in terms of age, period of infertility, fSH, LH, antral follicle count and their human menopausal gonadotropin (hMG) requirement (Table 1). Thirteen patients (23.6%) in cc group and 42 patients (76.4%) in tamoxifen group had positive serum beta hCG result. p-value was found to be significant (p = 0.016) (Table 2).

Conclusion: Tamoxifen was associated with better endometrial thickness and pregnancy rate when compared to clomiphene citrate in ovarian stimulation in IUI cycles.

INTRODUCTION

Ovulation is the central event in the reproduction cycle. Ovulatory disorders account for 20 to 25% of all cases of infertility. Successful therapy of anovulation is one of the most dramatic advances in infertility management. Nonsteroidal selective estrogen receptor modulators (SERM), such as clomiphene citrate (CC) and tamoxifen, are commonly used to induce ovulation. Selective estrogen receptor modulators are thought to act primarily by binding with estrogen receptors at the hypothalamus. This competitive inhibition results in a perceived drop in endogenous estrogen levels, eventually leading to increased gonadotropin secretion and subsequent induction of ovulation. Clomiphene citrate has been the first-line method of ovulation induction in couples with anovulatory infertility since its introduction in 1956. Approximately 80% of women ovulate while using clomiphene, however, only 40% of women will achieve pregnancy. Some authors have proposed that this discrepancy is due to the antiestrogenic effects of clomiphene on the uterus, cervix and vagina, resulting in a thin endometrial lining and poor cervical mucus. Another nonsteroidal SERM, tamoxifen, has also been used to induce ovulation. Although commonly used today as an adjuvant therapy in the treatment of breast cancer, its use as an ovulatory agent was first reported by Williamson and Ellis. Unlike clomiphene, tamoxifen acts as an agonist on the estrogen receptors of the vaginal mucosa and endometrium. Studies on the effects of tamoxifen on cervical mucus have been contradictory. A randomized controlled trial found that tamoxifen was as effective as clomiphene in inducing ovulation. Despite a trend toward improved pregnancy rates with tamoxifen, the study was underpowered to confirm this finding.

AIM

The study aimed to assess the effect of tamoxifen and CC on clinical outcome in ovarian stimulation in IUI cycles.
MATERIALS AND METHODS

It is a retrospective clinical study. Two hundred and seven women undergoing IUI cycles from July 2013 to July 2014 at Milann—The Fertility Centre, Bengaluru were analyzed. Tamoxifen was administered in the dose of 40 mg starting from day 2/3 of the menstrual cycle for a period of 5 days and CC was administered in the dose of 100 mg from day 2/3 of menstrual cycle for 5 days. Inj. HMG 75/150 IU was added according to the follicular response. Monitoring of ovulation was done by transvaginal ultrasound. Monitoring of ovulation was done by transvaginal ultrasound from day 5/6 till dominant follicle size was more than 18 mm. Highly purified hCG in the dose of 5000 IU was given. Double insemination was done at 24 and 36 hours. Ultrasound was done from day 11 onward. The occurrence of ovulation was documented by one or more of the following criteria:

- Development of dominant follicle ≥ 17 mm, followed by disappearance
- Reduction in size of dominant follicle by more than 5 mm
- A change in the shape and appearance of internal echoes within the follicle
- Appearance of free fluid in the pouch of Douglas.

Luteal phase support was given in form of dydrogesterone 10 mg twice a day for 14 days. Serum beta-hCG was done after 14 days.

Outcomes

Primary outcomes
- Clinical pregnancy rate

Secondary outcomes
- Endometrial thickness
- Number of follicles > 15 mm in size.

Clinical pregnancy defined as women with positive serum beta-hCG and ultrasound evidence of gestational sac.

Inclusion Criteria

Primary or secondary infertility due to:
- Ovulatory dysfunction
- Mild male infertility
- Unexplained infertility
- Tubal factor
- Age 18 to 35.

Exclusion Criteria

- Serious adverse effects under CC or known sensitivity to either tamoxifen or CC.
- Severe male factor infertility-TMC < 1 million/ml
- Severe endometriosis
- Poor ovarian responders (according to Bologna criteria).

STATISTICAL ANALYSIS

Statistical Methods

Descriptive and inferential statistical analysis has been carried out in the present study. Test of significance for variables: continuous scale-student t-test (two tailed, independent) and for categorical scale—Chi-square/Fisher exact test. The Statistical software namely SAS 9.2, SPSS 15.0, Stata 10.1, MedCalc 9.0.1, Systat 12.0 and R environment ver.2.11.1 were used for the analysis of the data.

RESULT

In our study, 76 patients received CC (37%) and 126 patients received tamoxifen (62.9%). Both the groups were comparable in terms of age, period of infertility, FSH, LH, antral follicle count and their hMG requirement (Table 1). Thirteen patients (23.6%) in CC group and 42 patients (76.4%) in tamoxifen group had positive serum beta hCG result p-value was found to be significant (p = 0.016) (Table 2).

INFERENCEs

Results from the study indicate that the mean number of follicles did not differ significantly in patients receiving clomiphene or tamoxifen with p-value being 0.629 (Table 2). Endometrial thickness in patients receiving CC was found to be less than patients receiving tamoxifen (p = 0.01) (Fig. 1). Pregnancy rates in patients receiving tamoxifen during IUI cycles is significantly higher than those receiving CC with p-value being 0.016 (Fig. 2).

DISCUSSION

Clomiphene citrate introduced by Greenblatt et al.\textsuperscript{2} is one of the most commonly used agents in ovulation induction.

Table 1: Comparison between baseline variables in both the groups (CC and TAM)

<table>
<thead>
<tr>
<th>Clinical variables</th>
<th>Protocol</th>
<th>Total</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CC (n = 76)</td>
<td>TAM (n = 129)</td>
<td>(n = 205)</td>
</tr>
<tr>
<td>Age in years</td>
<td>29.71 ± 3.51</td>
<td>29.12 ± 2.76</td>
<td>29.34 ± 3.06</td>
</tr>
<tr>
<td>Infertility (years)</td>
<td>3.05 ± 1.91</td>
<td>2.94 ± 1.71</td>
<td>2.98 ± 1.77</td>
</tr>
<tr>
<td>FSH</td>
<td>5.84 ± 2.01</td>
<td>5.97 ± 1.52</td>
<td>5.92 ± 1.72</td>
</tr>
<tr>
<td>LH</td>
<td>5.36 ± 2.94</td>
<td>5.43 ± 3.58</td>
<td>5.40 ± 3.35</td>
</tr>
<tr>
<td>AFC</td>
<td>7.04 ± 3.12</td>
<td>7.14 ± 3.08</td>
<td>7.10 ± 3.09</td>
</tr>
<tr>
<td>hMG</td>
<td>402.96 ± 254.62</td>
<td>449.42 ± 249.11</td>
<td>432.19 ± 251.55</td>
</tr>
</tbody>
</table>

CC: Clomiphene citrate; TAM: Tamoxifen; FSH: Follicle stimulating hormone; LH: Luteinizing hormone; AFC: Antral follicle count; hMG: Human menopausal gonadotropin
However, pregnancy rates (30–40%) with CC are not as good as ovulation rates (70–80%). Another downside of CC is the controversial suggestion that clomiphene use could be associated with epithelial ovarian cancer. Tamoxifen another antiestrogenic compound very similar structure to CC, in use as an anticancer agent has also been evaluated as a fertility agent. The mechanism of tamoxifen in improving folliculogenesis may involve a direct action on the ovary without intervention of hypothalalo-pituitary system as suggested in the studies by Fukushima et al. Tamoxifen also has a beneficial effect on the cervical mucus and the endometrium. Several studies have looked at clomiphene vs tamoxifen as first line therapy in anovulatory infertility.

In our study, 76 patients received CC (37%) and 126 patients received tamoxifen (62.9%). Both the groups were comparable in terms of age, period of infertility, FSH, LH, antral follicle count and their hMG requirement. Thirteen patients (23.6%) in CC group and 42 patients (76.4%) in tamoxifen group had positive serum beta-hCG result p-value was found to be significant (p = 0.016). In a meta-analysis conducted by Steiner AZ et al 2005 the use of tamoxifen or CC resulted in similar ovulation rates [odds ratio (OR) 0.755, 95% confidence interval (CI) 0.513–1.111]. There was no benefit of tamoxifen over CC in achievement of pregnancy per cycle (OR 1.056, 95% CI 0.583–1.912) or per ovulatory cycle (OR 1.162, 95% CI 0.632–2.134).The ovulation rates were high in both groups; however, pregnancy rates were much lower. Although the odds of pregnancy were higher after ovulation with tamoxifen, this finding was not statistically significant. Despite the theoretical benefits of tamoxifen, this meta-analysis failed to find a significant benefit of tamoxifen over clomiphene for inducing pregnancy. The similarity in ovulation rates differs from the conclusions by Borenstein et al who found in a retrospective study of 43 clomiphene-resistant patients that tamoxifen was a superior ovulatory agent. However, Gerhard and Runnebaum concluded that ovulation rates with tamoxifen did tend to be higher than those with clomiphene in women with oligomenorrhea. Their findings on the relative effects of clomiphene and tamoxifen on pregnancy rates or outcome were inconclusive. Unlike the pooled odds ratio for ovulation induction, there was a fairly imprecise estimate of the odds of pregnancy with tamoxifen vs clomiphene.

In our study, the endometrial thickness in CC group was 8.69 ± 1.03 and in TAM group it was 9.15 ± 1.44 which was found to be significant (p = 0.014). The pregnancy rate in CC group was 17.1 and 32.6% in TAM group (p = 0.016). Our findings on the relative effects of clomiphene and tamoxifen on pregnancy rates found higher pregnancy rate in TAM group. In study by Boostanfar et al 2000, the overall rate of ovulation in the TMX group was 50 of 113 (44.2%) and in the CC group, 41 of 91 (45.1%). There were 10 pregnancies in the TMX group and six pregnancies in the CC group. The cycle fecundity per ovulatory cycle was 20.0% in the TMX group and 14.6% in the CC group. The overall rate of ovulation and pregnancy were similar with TMX and CC. This study demonstrated that TMX is an effective, but not superior, alternative to CC for the induction of ovulation in infertile women. However, this study had a small sample size in which 98 anovulatory
women without other causes of infertility were taken. In our study, Tamoxifen was associated with better endometrial thickness and pregnancy rate than compared to CC. However, a potential limitation of our study is the retrospective design. Secondly, the data taken for the study were taken from a single center, so the sample was small, and the generalizability of the findings may be limited. Thus, more studies are required to assess the clinical outcomes and effectiveness between both the drugs.

CONCLUSION

Tamoxifen was associated with better endometrial thickness and pregnancy rate than compared to CC in ovarian stimulation in IUI cycles.

REFERENCES